Early analysis of immunotherapy safety and benefit in metastatic/recurrent/persistent cervical cancer treated with first-line pembrolizumab: a tertiary centre experience

International Journal of Gynecological Cancer 2026

View at publisher

Authors: Slobodan S. Kutic, Simonida Bobić, Lidija Pavlovic, Milana Matović, Jovana Mijucic, Marijana Milović-Kovačević

DOI: 10.1016/j.ijgc.2025.103269

Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Endometrial and Cervical Cancer Treatments Cervical Cancer and HPV Research